Zongertinib Proves Clinically Active With Low Rate of EGFR-Mediated AEs in HER2-Mutant Solid Tumors

Treatment with at least 90 μg/kg of the novel DLLC-targeting T-cell–engager BI 764532 was well tolerated and led to tumor shrinkage in patients with small cell lung cancer and neuroendocrine carcinoma.

Related Keywords

Tokyo ,Japan ,Australia ,United States ,America ,Noboru Yamamoto ,National Cancer Center Hospital ,Department Of Experimental Therapeutics ,Lung Cancer ,Experimental Therapeutics ,Middle East ,World Conference On Lung Cancer ,Her2 Mutant Solid Tumors ,Zongertinib ,